Article

The Center for Cancer and Blood Disorders Joins AON

American Oncology Network, LLC (AON) is pleased to announce that The Center for Cancer and Blood Disorders (CCBD), a leading community oncology and hematology practice serving Bethesda and Germantown, Maryland, has joined AON.

Fort Myers, Fla., May 4, 2020—American Oncology Network, LLC (AON) is pleased to announce that The Center for Cancer and Blood Disorders (CCBD), a leading community oncology and hematology practice serving Bethesda and Germantown, Maryland, has joined AON, effective May 1, 2020. The Center for Cancer and Blood Disorders team includes three medical oncologists providing the highest quality of care, with state-of-the-art technology, and the latest advances in clinical research and therapies. The practice regularly performs more than 300 clinical trials on new and developing diagnostic devices and techniques for cancer and diseases. The partnership with AON will help expand patient services such as home delivery of oral oncolytic medications, patient education, and 24/7 pharmacy assistance.

AON CEO Brad Prechtl, MBA stated, “We are excited for Drs. Boccia, Priego and Goldstein and the entire Center for Cancer and Blood Disorders team to join our growing network of community oncologists helping to bring the very best in cancer care and treatment to patients, close to where they live.”

“The Center for Cancer and Blood Disorders will remain focused on integrating the best medicine in an environment that helps patients overcome obstacles such as easier access to medications and financial counseling,” said AON Board Member & Chairman Dr. Stephen Orman.

Read the full press release here.

Related Videos
Jessica K. Paulus, ScD, Ontada
ASPC Congress Logo
Interview with Joseph Mikhael, MD, MEd, FRCPC, FACP
Jessica K. Paulus, ScD, Ontada
Michael A. Choti, MD, MBA
Kathryn Lindley, MD, FACC
Dr Ajay Goel
Dr Ajay Goel
Julie Patterson, PharmD, PhD
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Related Content
CH LogoCenter for Biosimilars Logo